Amazfit’s much-hyped budget Garmin rival has built-in music storage and claims three-week battery life

Amazfit launched the Active Max, a 48.5 x 48.5 x 12.2mm, 39.5g sports smartwatch priced at £169 / $170 / €169.90, targeting budget buyers who consider premium Garmin and Apple devices. Key specs include a 658mAh battery (quoted 25 days daily use, 13 days heavy use, 64 hours GPS), 1.5-inch 480x480 60Hz AMOLED (up to 3,000 nits), GNSS from Airoha, PPG heart-rate, SpO2, temperature and barometric sensors, offline topographic/ski maps, NFC in supported regions and 4GB onboard music storage; availability is via Amazfit’s store and select partners. The combination of advanced navigation/health features and aggressive pricing could intensify competition in the wearable segment and pressure margins or pricing strategies of higher-end rivals.

Analysis

Market structure: The Active Max (£/$170) intensifies competition at the sub-$200 wearable tier and directly benefits budget OEMs (Amazfit/Zepp), value-focused retailers and GNSS/sensor suppliers that can scale volume. Premium vendors (GRMN, to a lesser extent AAPL at the very high end) face ASP pressure in mid-tier lines; expect 5–10% downward pressure on mid-range watch ASPs over 12–18 months if others match specs. Cross-asset effects are muted but could shave a few basis points off consumer discretionary cyclicals’ credit spreads if a broader price war emerges.

Risk assessment: Tail risks include product-quality recalls, map/licensing disputes or regulatory action on health metrics or payments (NFC), any of which could crater adoption in 30–90 days. Immediate impact is media-driven (days–weeks), Q1 retail sales will show demand validation (weeks–months), and structural share shifts require 12–36 months. Hidden dependency: software/ ecosystem stickiness (maps, accuracy, app engagement) is the real moat; hardware wins alone won’t sustain higher ARPU.

Trade implications: Tactical trades: long Zepp Health (ZEPP) to capture share gains; hedge or short GRMN to express mid-tier margin risk. Use option structures to limit drawdowns — e.g., 6–9 month ZEPP call spreads and 3-month GRMN puts sized 1–3% portfolio. Rotate 3–5% consumer discretionary allocation from premium wearable exposure into budget OEMs and component suppliers over the next 6–12 months.

Contrarian angles: Consensus may overstate Amazfit’s disruptive power — Garmin’s loyal user base, superior mapping/accuracy and after-sales service historically defend price points (see Fitbit vs Garmin historical dynamics). If independent GPS/HR accuracy tests (30–60 days) show >15% degradation vs Garmin, the market reaction is justified; otherwise early selloffs in GRMN could be an overreaction and a tactical long-add opportunity.

Key Decisions for Investors

• Establish a 2–3% long position in Zepp Health (ZEPP) within 7 trading days; target +40% in 6–12 months, set hard stop-loss at -15%; size options exposure via a 6–9 month call spread 20% OTM to limit capital at risk.
• Initiate a 1–2% short or buy 3-month GRMN puts 15% OTM to express mid-tier margin pressure; cover if Garmin announces a formal mid-tier price cut or feature match, or if GRMN falls >30% from entry.
• Implement a pair trade: long ZEPP / short GRMN at a 2:1 notional ratio, rebalance monthly and close or reassess after Q1 retail figures (within 90 days) or if independent accuracy tests show ZEPP returns rate >5% or >15% GPS error vs GRMN.
• Rotate 3–5% of consumer discretionary exposure into component suppliers (e.g., GNSS/ SoC suppliers such as MediaTek-equivalent listed tickers) using 6–12 month call spreads to capture volume-driven upside while capping downside; review after 6 months.